News | June 03, 2026
Granules Pharmaceuticals receives USFDA EIR for Chantilly facility
This facility plays an important role in Granules’ global manufacturing and supply network
This facility plays an important role in Granules’ global manufacturing and supply network
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
The facility sets a new benchmark in respiratory diagnostics
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
Novel fluorescent nanosensor enables real-time detection of indole-3-propionic acid (IPA), paving the way for faster gut health screening, point-of-care diagnostics, and wearable monitoring devices
The safety profile was described as manageable, though not without notable toxicities
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
The accepted studies span several critical areas of oncology, including nutrition, genomics, precision medicine, patient-reported outcomes, and community-based cancer care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
